These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12709749)

  • 1. Radiographic features of bisphosphonate therapy in pediatric patients.
    Grissom LE; Harcke HT
    Pediatr Radiol; 2003 Apr; 33(4):226-9. PubMed ID: 12709749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiological features of bisphosphonate therapy in children with osteogenesis imperfecta.
    Bin-Abbas BS; Al-Ashwal AA; Al-Zayed ZS; Sakati NA
    Saudi Med J; 2004 Nov; 25(11):1772-3. PubMed ID: 15573233
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of denosumab on the growing skeleton in osteogenesis imperfecta.
    Hoyer-Kuhn H; Semler O; Schoenau E
    J Clin Endocrinol Metab; 2014 Nov; 99(11):3954-5. PubMed ID: 25148238
    [No Abstract]   [Full Text] [Related]  

  • 6. Osteogenesis Imperfecta: Skeletal Outcomes After Bisphosphonate Discontinuation at Final Height.
    Robinson ME; Trejo P; Palomo T; Glorieux FH; Rauch F
    J Bone Miner Res; 2019 Dec; 34(12):2198-2204. PubMed ID: 31356699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fracture during intravenous bisphosphonate treatment in a child with osteogenesis imperfecta: an argument for a more frequent, low-dose treatment regimen.
    Biggin A; Briody JN; Ormshaw E; Wong KK; Bennetts BH; Munns CF
    Horm Res Paediatr; 2014; 81(3):204-10. PubMed ID: 24356182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate treatment of pediatric bone disease.
    Speiser PW; Clarson CL; Eugster EA; Kemp SF; Radovick S; Rogol AD; Wilson TA;
    Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The radiology of osteogenesis imperfecta].
    Orzincolo C; Castaldi G; Scutellari PN; Ghedini M; Franceschini F; Bagni B
    Radiol Med; 1992 Nov; 84(5):557-66. PubMed ID: 1475419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term effects of switching from active intravenous bisphosphonate treatment to low-dose maintenance therapy in children with osteogenesis imperfecta.
    Biggin A; Zheng L; Briody JN; Coorey CP; Munns CF
    Horm Res Paediatr; 2015; 83(3):183-9. PubMed ID: 25676713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
    Rauch F; Munns C; Land C; Glorieux FH
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
    Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
    Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
    Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
    J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    Glorieux FH; Bishop NJ; Plotkin H; Chabot G; Lanoue G; Travers R
    N Engl J Med; 1998 Oct; 339(14):947-52. PubMed ID: 9753709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta.
    Land C; Rauch F; Glorieux FH
    J Bone Miner Res; 2006 Mar; 21(3):374-9. PubMed ID: 16491284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.
    Arikoski P; Silverwood B; Tillmann V; Bishop NJ
    Bone; 2004 Mar; 34(3):539-46. PubMed ID: 15003801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
    Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
    Shah I; Johari A
    Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.